Tempest Therapeutics Inc expected to post a loss of 92  cents a share - Earnings Preview

Tempest Therapeutics

09/08/2022 03:01

* Tempest Therapeutics Inc  TPST.OQ   TPST.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 10 (estimated). 
    * ​Refinitiv's mean analyst estimate for Tempest
Therapeutics Inc
is for a loss of 92 cents per share. For the same quarter last
year, the company reported a loss of $7.63 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $22.5​, above​ its last closing price
of $2.25. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -1.12       -1.12      -1.18     Missed  -5.7
 Dec. 31 2022              -1.23      -1.12     Beat    9.1
 Sep. 30 2021  -1.04       -1.05      -1.21     Missed  -15.6​
 Jun. 30 2021  -0.87       -0.87      -7.63     Missed  -772
 ​​Mar.                    -5.25      -6.60     Missed  -25.7
 31 2021                                                
 Dec. 31 2020              -5.15      -5.85     Missed  -13.6​
 Sep. 30 2020  -7.03       -6.90      -5.10     Beat    26.1
 Jun. 30 2020  -8.39       -8.20      -8.40     Missed  -2.4
 This summary was machine generated August 9 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated